2025
A randomized controlled trial comparing embryo vitrification with slush nitrogen to liquid nitrogen in women undergoing frozen embryo transfer: embryology and clinical outcomes
Klimczak A, Osman E, Esbert M, Yildirim R, Whitehead C, Herlihy N, Hanson B, Roberts L, Seli E, Scott R. A randomized controlled trial comparing embryo vitrification with slush nitrogen to liquid nitrogen in women undergoing frozen embryo transfer: embryology and clinical outcomes. Human Reproduction 2025, 40: 426-433. PMID: 39836897, DOI: 10.1093/humrep/deaf003.Peer-Reviewed Original ResearchFrozen embryo transferRandomized Controlled TrialsPregnancy outcomesIVF stimulationPre-clinical trialsEmbryo transferPregnancy rateFutility analysisPost-warming survival rateDATE OF FIRST PATIENT’S ENROLMENT:University-affiliated infertility centerClinical pregnancy rateEmbryo transfer outcomesSustained implantation ratesPreimplantation genetic testingFIRST PATIENT’S ENROLMENTBlastocyst biopsyEmbryological outcomesBlastocyst survivalEmbryo vitrificationHuman oocytesMiscarriage rateImplantation rateNo significant differenceBaseline characteristics
2019
Phase IB/II Randomized Study of FOLFIRINOX Plus Pegylated Recombinant Human Hyaluronidase Versus FOLFIRINOX Alone in Patients With Metastatic Pancreatic Adenocarcinoma: SWOG S1313
Ramanathan RK, McDonough SL, Philip PA, Hingorani SR, Lacy J, Kortmansky JS, Thumar J, Chiorean EG, Shields AF, Behl D, Mehan PT, Gaur R, Seery T, Guthrie KA, Hochster HS. Phase IB/II Randomized Study of FOLFIRINOX Plus Pegylated Recombinant Human Hyaluronidase Versus FOLFIRINOX Alone in Patients With Metastatic Pancreatic Adenocarcinoma: SWOG S1313. Journal Of Clinical Oncology 2019, 37: jco.18.01295. PMID: 30817250, PMCID: PMC6494359, DOI: 10.1200/jco.18.01295.Peer-Reviewed Original ResearchConceptsMetastatic pancreatic cancerMedian overall survivalCombination armOverall survivalHazard ratioControl armPhase II open-label studyTreatment-related grade 3Adequate organ functionPhase II dosageOpen-label studyPrimary end pointMetastatic pancreatic adenocarcinomaOS hazard ratioHA statusDose-finding studyInterim futility analysisRecombinant human hyaluronidaseEnoxaparin prophylaxisThromboembolic eventsPerformance statusProlong survivalRandomized studyFutility analysisGood PS
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply